Max Wang, CEOShanghai MediumBank Biotechnology is meeting these demands head-on by pushing the boundaries of CHO cell line productivity through AI-driven media development. The company specializes in chemically defined formulations and platform-wide compatibility, delivering end-to-end upstream solutions—from clone screening and media development to process optimization and scale-up support. “By combining AI-driven optimization with our deep bioprocess expertise, we’re setting a new standard in CHO cell culture to help our clients accelerate innovation, ensure quality and reduce development costs,” says Max Wang, CEO.
MediumBank champions an agile approach to quality and cost reduction in customizing media. To achieve desired product quality attributes, it integrates quality by design principles, AI analytics and advanced screening technologies. Through its artificial intelligence medium development (AIMD) R&D platform, the company uses a rich formula library, AI analysis and high-throughput screening to develop culture media within one to three months for safer, more effective drugs.
Building on this precision, its chemically defined, animal-derived component-free CHO cell culture platform delivers high-performance media for scalable, cost-effective and GMP-compliant biomanufacturing. Validated by over 600 enterprises, this platform marks a forward step by occupying more than 30 percent of China's market share.
Pioneering CHO Cell Culture Technology across APAC
Instead of conventional one-size-fits-all approaches, MediumBank prioritizes tailoring and optimizing different culture media. The company’s seasoned researchers conduct detailed analyses at every stage of the production process, identifying and resolving issues by fine-tuning media and process parameters. This hands-on, analytical approach ensures clients can overcome even the most difficult regulatory or production hurdles.
As a trusted name in APAC bioproduction, MediumBank offers innovative medium optimization and development services. The company delivers media that boost yields by up to 300 percent while reducing development time by 40 percent and costs by 25 percent. Complementing this performance edge, the company also provides OEM media services and supernatant analysis, supporting biopharma from development to commercialization across cell lines such as CHO-K1, CHO-S, CHO-DG44, and CHOZN.
-
By combining AI-driven optimization with our deep bioprocess expertise, we’re setting a new standard in CHO cell culture—helping our clients accelerate innovation, ensure quality and reduce development costs
Instead of conventional one-size-fits-all approaches, MediumBank prioritizes tailoring and optimizing different culture media. The company’s seasoned researchers conduct detailed analyses at every stage of the production process, identifying and resolving issues by fine-tuning media and process parameters. This hands-on, analytical approach ensures clients can overcome even the most difficult regulatory or production hurdles.
MediumBank’s basal media support high cell growth, and formulas like CHO MaxA5 plus and CHO 375 increase yields and preserve product quality. Its feeding media combinations maintain cell viability above 95 percent and increase expression levels by 30 to 100 percent, while quality regulators precisely control attributes like glycosylation and charge heterogeneity.
All its additives, including CellMaxer and MaxGLN, enhance cell proliferation, suppress late-stage apoptosis and boost the overall Integral of Viable Cell Concentration (IVCC) throughout the culture cycle. These solutions optimize critical quality attributes in three tests, improving process efficiency and batch consistency.
This impact is evident in MediumBank’s success stories. One notable example involved a client whose product yield was limited by low output, high production costs and abnormal lactate metabolism during the final stage of cell culture. Seeking multiple basal and feed media to improve nutrient supply and control metabolism, the client approached the MediumBank team to optimize their production process. In response, the team conducted six rounds of customized medium development, which resulted in tripled yields, reduced costs and more stable production batches.
MediumBank’s commitment to such achievements goes beyond technical solutions. By aligning with clients’ timelines and providing full-process technical support, the company empowers biopharmaceutical organizations to achieve greater efficiency, quality and innovation. As the industry raises the bar for excellence, MediumBank stands ready to help clients achieve faster, more reliable results.
Shanghai MediumBank: Powering Bioprocess Innovation with Customized Media Solutions
Max Wang, CEO and the Head of the R&D Department
We believe the success of a biotherapeutic product begins with a precise, scalable, and stable media strategy. Our integrated platforms and MOD service deliver customized, scalable solutions that accelerate time-to-market, optimize costs, and ensure supply chain reliability, turning scientific potential into commercial reality.
CHO Cell Culture Info
Q1
Why is Shanghai MediumBank Biotechnology recognized among leading CHO Cell Culture Solutions providers?
Shanghai MediumBank Biotechnology has gained strong recognition in CHO Cell Culture Solutions by focusing on high-performance chemically defined media designed for biologics production. The company supports biopharmaceutical manufacturers with optimized CHO (Chinese Hamster Ovary) cell culture systems that improve protein expression, increase yield, and enhance process consistency. Its solutions are widely validated across monoclonal antibody, fusion protein, and vaccine development programs, reflecting strong industry adoption across global biomanufacturing workflows.
Q2
What differentiates MediumBank in CHO cell culture development?
A defining strength of MediumBank in CHO Cell Culture Solutions is its AI-driven media optimization platform, which enables rapid development of chemically defined media tailored to specific cell lines and production goals. Instead of relying on generic formulations, it applies data-driven screening and process modeling to refine nutrient composition and metabolic balance. This approach helps improve cell viability, enhance productivity, and reduce development timelines, particularly in high-density CHO suspension cultures used for therapeutic protein production.
Q3
How does MediumBank support biopharmaceutical manufacturing workflows?
MediumBank delivers integrated CHO Cell Culture Solutions that cover the full upstream bioprocessing chain, including clone screening, media development, process optimization, and scale-up support. Its chemically defined media platforms are compatible with multiple CHO cell lines such as CHO-K1, CHO-S, CHO-DG44, and CHOZN, enabling flexible application across early-stage research and commercial production. This end-to-end support structure helps biopharma companies maintain consistency from laboratory development to GMP manufacturing.
Q4
What role does media formulation play in CHO cell performance?
Media formulation is central to MediumBank’s CHO Cell Culture Solutions because nutrient composition directly influences cell growth, protein yield, and product quality attributes. The company develops specialized basal and feed media designed to optimize metabolism, maintain high viability, and control critical quality attributes such as glycosylation. Its formulations are engineered to support high-density cultures while maintaining stable production performance across multiple bioprocess cycles.
Q5
How does the company ensure scalability and process consistency?
Consistency and scalability in CHO Cell Culture Solutions are achieved through standardized chemically defined media systems and GMP-aligned production processes. MediumBank operates production facilities built to pharmaceutical-grade standards and applies quality-by-design principles to ensure reproducibility across batches. This allows biopharmaceutical clients to transition smoothly from development-scale experiments to large-scale commercial manufacturing without major process redesign.
Q6
Why is MediumBank relevant to modern biologics and therapeutic production?
MediumBank is highly relevant to today’s biologics industry because demand for efficient, high-yield CHO-based production systems continues to grow in monoclonal antibodies, vaccines, and cell and gene therapy applications. Its CHO Cell Culture Solutions address key industry needs such as cost reduction, faster development timelines, and improved product quality consistency. By combining AI-enabled optimization with chemically defined media innovation, the company supports next-generation biomanufacturing efficiency at scale.
